<SEC-DOCUMENT>0001493152-24-048004.txt : 20241127
<SEC-HEADER>0001493152-24-048004.hdr.sgml : 20241127
<ACCEPTANCE-DATETIME>20241127161728
ACCESSION NUMBER:		0001493152-24-048004
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20241127
DATE AS OF CHANGE:		20241127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AIM ImmunoTech Inc.
		CENTRAL INDEX KEY:			0000946644
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				520845822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-27072
		FILM NUMBER:		241511429

	BUSINESS ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801
		BUSINESS PHONE:		352-448-7797

	MAIL ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEMISPHERX BIOPHARMA INC
		DATE OF NAME CHANGE:	19950614
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>formdefa14a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>

</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 OR 15(d) of The</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported) November 25, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>AIM
IMMUNOTECH INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT>001-27072</FONT></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>52-0845822</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(state
    or other jurisdiction</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2117
    SW Highway 484, Ocala FL</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>34473</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <FONT><B>(352)</B>
</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>448-7797</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9746;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 27.8pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE
    American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01 Regulation FD Disclosure.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 27, 2024, AIM ImmunoTech Inc. (the &#8220;Company&#8221;) issued a press release regarding the establishment of a Cash
Conservation Plan, as described in Item 8.01 hereto. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated
by reference in this Item 7.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information furnished in this Item 7.01, including Exhibit 99.1, is being furnished, and shall not be deemed to be &#8220;filed&#8221;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject
to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01 Other Events.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2024, the Compensation Committee (the &#8220;Committee&#8221;) of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;)
established a cash conservation plan (the &#8220;Cash Conservation Plan&#8221;). Pursuant to the Cash Conservation Plan, the Company&#8217;s
independent directors will receive 100% of their Board compensation in shares of the Company&#8217;s common stock, effective immediately.
They will not receive any director compensation in cash. This does not apply to Mr. Equels because he is not an independent director
and he does not receive any compensation for serving as a director. In lieu of cash payments, each independent director will receive
twice-a-month stock grants at a valuation equal to the closing price of the shares of the Company&#8217;s common stock on the last trading
day before such grants are made. The Cash Conservation Plan will stay in effect for as long as the Committee determines, in its sole
discretion, consistent with the compensation policies of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01. Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are filed herewith:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number</B></FONT></TD>
  <TD STYLE="padding-bottom: 1pt; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex99-1.htm">Press Release dated November 27, 2024.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">104</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Cover Page Interactive Data File (embedded within the Inline XBRL document)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline">SIGNATURES</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">AIM ImmunoTech Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: November 27, 2024</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Thomas
K. Equels</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Thomas K. Equels, CEO</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AIM
ImmunoTech Announces Cash Conservation Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Independent
Board Members to Receive 100% of Director Compensation in AIM Stock</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Follows
Previously Disclosed Amendments to Executive Employment Agreements to Reduce Cash Component of Compensation for CEO and COO</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
and Management are Deeply Aligned with All AIM Shareholders and Remain Committed to Unlocking the Full Potential of Ampligen</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OCALA,
Fla.</B>, November 27, 2024 &mdash; AIM ImmunoTech Inc. (NYSE American: AIM) (&ldquo;AIM&rdquo; or the &ldquo;Company&rdquo;)
today announced that the Compensation Committee of the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;) has established a
cash conservation plan (the &ldquo;Cash Conservation Plan&rdquo;). The Cash Conservation Plan is a key part of the Board and management
team&rsquo;s efforts to bolster the Company&rsquo;s ability to maintain its momentum in achieving key clinical milestones in areas with
critical unmet needs &ndash; which we believe will ultimately create increased shareholder value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first steps of the Cash Conservation Plan encompass the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
                                            immediately, AIM&rsquo;s independent directors will receive 100% of their Board compensation
                                            in shares of the Company&rsquo;s common stock. They will not receive any director compensation
                                            in cash. In lieu of cash payments, each independent director will receive twice a month stock
                                            grants, at a valuation equal to the closing price of AIM shares on the last trading day before
                                            such grants are made.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            previously disclosed, AIM Executive Vice Chairman of the Board, CEO &amp; President Thomas
                                            K. Equels and Chief Operating Officer Peter W. Rodino agreed to amend their employment agreements,
                                            effective as of September 11, 2024, to reduce the cash portion of their base salaries and
                                            receive shares of AIM stock equal to the value of those reductions. The amount of reduced
                                            cash compensation is $200,000 for Mr. Equels and $50,000 for Mr. Rodino. Mr. Equels will
                                            continue to receive no additional compensation for his Board service. More details are available
                                            in the Company&rsquo;s Quarterly Report on Form <U>10-Q</U> for the period ended June 30,
                                            2024.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notably,
Mr. Equels purchased 361,458 of the Company&rsquo;s shares between November 2023 and November 2024 (231,458 via the Employee &amp; Director
Stock Purchase Plan that allows executives to put cash back into the Company, and 130,000 on the open market, with the most recent purchase
being 20,000 shares on November 21, 2024). None of the group of activist investors&rsquo; (collectively, the &ldquo;Activist Group&rdquo;)&nbsp;
nominees appear to have purchased AIM stock in all of 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
William M. Mitchell, Chairman of the Board, stated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
Board is unanimous in its strong belief in Ampligen&rsquo;s significant potential to help patients with unmet lethal medical needs &ndash;
especially in high value indications &ndash; and its ability to thereby deliver enhanced value for all shareholders. By implementing
the Cash Conservation Plan, the Board and management are further aligning ourselves with all shareholders and helping to ensure the Company
can achieve its full potential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no doubt that many shareholders have endured declines in the value of their investment, but it is imperative to recognize that as
a research and development company, our primary way to deliver significant value for all shareholders is to commercialize Ampligen to
help the most patients possible. That is why we remain focused on maintaining sufficient runway to advance our clinical pipeline, especially
in oncology, which we believe will best position the Company for long-term value creation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
will continue to share additional components of its Cash Conservation Plan going forward.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
also encourages shareholders to vote <B>FOR</B> the Board&rsquo;s incumbent candidates &ndash; <B>Stewart L. Appelrouth</B>, <B>Nancy
K. Bryan</B>, <B>Thomas K. Equels</B> and <B>Dr. William M. Mitchell</B> &ndash; in connection with the upcoming 2024 Annual Meeting
of Stockholders (the &ldquo;Annual Meeting&rdquo;), presently scheduled for December 17, 2024, on the <B><U>WHITE</U></B> universal proxy
card.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information on how to vote, visit: <U>www.SafeguardAIM.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
AIM ImmunoTech Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers,
immune disorders and viral diseases, including COVID-19. The Company&rsquo;s lead product is a first-in-class investigational drug called
Ampligen<SUP>&reg;</SUP> (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical
trials for globally important cancers, viral diseases and disorders of the immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit <U>aimimmuno.com</U> and connect with the Company on <U>X</U>, <U>LinkedIn</U>, and <U>Facebook</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the &ldquo;PSLRA&rdquo;).
Words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;continue,&rdquo;
&ldquo;believe,&rdquo; &ldquo;potential,&rdquo; &ldquo;upcoming&rdquo; and other variations thereon and similar expressions (as well
as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of
these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to
date does not guarantee that Ampligen will be approved as a treatment or therapy for any diseases or conditions. The Company urges investors
to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary
statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the U.S. Securities and
Exchange Commission (the &ldquo;SEC&rdquo;). You are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe
harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements
to reflect events or circumstances that occur after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Important
Additional Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be &ldquo;participants&rdquo;
(as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company&rsquo;s
stockholders in connection with the Annual Meeting. The Company filed its definitive proxy statement (the &ldquo;Definitive Proxy Statement&rdquo;)
and a <B>WHITE </B>universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company&rsquo;s
stockholders. <B>STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL
PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE
ANNUAL MEETING.</B> The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct
and indirect interests, by security holdings or otherwise, in the Company&rsquo;s securities and can be found in the section titled &ldquo;Principal
Stockholders&rdquo; of the Definitive Proxy Statement and available <U>here</U>. Information regarding subsequent changes to their holdings
of the Company&rsquo;s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company&rsquo;s website
available <U>here</U> or through the SEC&rsquo;s <U>website at www.sec.gov</U>. Stockholders will be able to obtain the Definitive Proxy
Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC&rsquo;s
website at <U>www.sec.gov</U>. Copies will also be available at no charge at the Company&rsquo;s website at <U>https://aimimmuno.com/sec-filings/</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JTC
Team, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jenene
Thomas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">908-824-0775</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>AIM@jtcir.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Longacre
Square Partners</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe
Germani / Miller Winston</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>AIM@longacresquare.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !K ,@# 2(  A$! Q$!_\0
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MQUH_PQ\"^+/B!KA6/1/".DW6L:FQ;8&@MR@D);:VW)<8;:W)Z9YKT*=F"2*
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M7%F+74+/3[FXMK;48_,M3\EZL*7$8R<0R C)YKM?^#G+_@HA#\#?V>XOV2/
M^H*GQ,^.NG.VN/#(IG\,^%+:]TNZ8WXC;S8%U[39-1M(1]V0J02RC%?Y[%I!
M#;6UM;JV(+6!((1'B-"JD%))-O\ &5Q"20=_WB<DBOZ \!_ 3*.-N',;Q+QA
M@L97P6(KT)Y7AZ.,>&J5<)2K2H5\13ANH<U-OF>\5&4$^:Y\;QIQIB<GQ4\)
M@)*4Z+IQJ)7?).=/F<6]5=Z6LEJIIWY=?].#_@G!_P %[O@G_P %(OV@KO\
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M['YZ/_P7Y_X+*^8Q3_@F[\1602B-=WP<\:QS0QR#^)3H)<!O4X)Y]<'\A?\
M@I)\:?VZ_P#@HO=^&_'?Q._X)R_$SX>?$#P/'J!O/B1X;^#/C*PO]=\/)8*\
ML.N7::"HGLM-MK?R3+-(4@2++E-K5_4-)_P=:_\ !/\ B21V^'/Q[)5=Q)\
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MCT_QMX?FMK:2%);HP0VRZAHKW2V&HQ0A/,GLII0@#8'[\_\ !J)^U?XD\/\
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M;+&A906+XW''7BO1O!'A[Q''_P '7OB[7KKPGKTWAU;O2VMM<N-(O8M'C#_
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33YH^WK332MO)1M9WV45UUW/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
